|
|
Effect of Cyclosporine Combined with Methylprednisolone Sodium Succinate on Serum Fibrosis Index and Urinary Beta 2-MG and mALB in Patients with Paraquat-induced Pulmonary Fibrosis |
FU Zhibin, WANG Zhenzhen |
Chengdu Military Area Government Hospital, Sichuan Chengdu 610000, China |
|
|
Abstract Objective: To study effect of cyclosporine combined with methylprednisolone on paraquat induced pulmonary fibrosis in patients with serum fibrosis index and its effects on urine Urinary beta 2- microspheres (beta 2-MG) and microalbuminuria (mALB). Methods: 102 patients of paraquat induced pulmonary fibrosis who received therapy from Apr. 2015 to Apr. 2017 in our hospital were selected as research objects. According to draw method, all the patients were divided into the experimental group (n=50) and the control group(n=52). Two groups were given gastrointestinal lavage, nutritional supplements, analgesia, antibiotics, infection prevention and other conventional treatment, while the experimental group was on this basis, treated with cyclosporine combined with methylprednisolone, cyclosporin injection every time 5mg/kg, methylprednisolone every time 1000mg, once a day, after 4 days of treatment, decrease. Then serum fibrosis markers Hyaluronic acid (HA), laminin (LN), type IV collagen (CIV) and type III procollagen, Matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase inhibitor (T1MP-1) levels, urinary beta 2-MG, mALB levels, and Pulmonary high-resolution CT (HRCT) scores were compared. Results: The levels of HA, LN, C, IV and PC III in the experimental group were significantly lower than the control group(P<0.05); MMP-9, T1MP-1 level were significantly lower than the control group(P<0.05); β2-MG, mALB level were significantly lower than the control group(P<0.05); HRCT score were significantly lower than the control group(P<0.05). Conclusion: Cyclosporin combined with methylprednisolone sodium succinate can significantly reduce the index of serum fibrosis in patients with paraquat induced pulmonary fibrosis, alleviate the process of pulmonary fibrosis, reduce the level of urinary beta 2-MG and mALB, and reduce renal function damage.
|
|
|
|
|
[1] 刘欣梦,刘伟丽,钱令嘉.重要脏器纤维化病变治疗药物的研究进展[J].中国药理学与毒理学杂志,2014,28(4):587~593. [2] 付显芬,罗真春.环孢素联合甲泼尼龙琥珀酸钠冲击治疗对急性百草枯中毒患者肺纤维化的影响[J].中国药房,2016,27(23):3261~3263. [3] 朱莉莉,代华平,王辰.特发性肺纤维化急性加重研究进展[J].华西医学,2018,33(1):93~98. [4] 赫英春.血液灌流联合环孢素A冲击治疗急性百草枯中毒的疗效观察[J].齐齐哈尔医学院学报,2016,37(31):3901~3902. [5] 肇阳.静脉滤过联合血液灌流治疗百草枯中毒致肺纤维化的疗效观察[J].社区医学杂志,2017,15(3):44~46. [6] 郭迎科,李瑞琴,丁玉文.肺纤维化发病机制的细胞因子研究进展[J].亚太传统医药,2016,12(19):69~72. [7] 朱鹏飞,薛顺青,孙茂峰.早期大剂量甲基氢化泼尼龙冲击治疗对百草枯(PQ)中毒患者病死率、肺纤维化发生率的影响[J].世界最新医学信息文摘,2017,17(72):44~46. [8] 杨颖,华树成,白晓雪,等.特发性肺纤维化治疗的研究进展[J].中国老年学杂志,2015,35(9):2559~2561. [9] 陈孟毅,孟爱民.肺纤维化动物模型及研究进展[J].中国比较医学杂志,2016,26(6):88~93. [10] 胡丽华,袁影,周仪华.肺纤维化疾病早期生物标志物研究进展[J].生命化学,2016,36(2):208~212. |
|
|
|